Preliminary Safety and Tolerability of CD19x22 CAR T Cells in Adolescent and Adult R/R B-NHL Patients

NCT05098613 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

68

Enrollment

OTHER

Sponsor class

Conditions

Non-Hodgkin Lymphoma
B-cell Non-Hodgkin Lymphoma (B-NHL)
Mantle Cell Lymphoma (MCL)
CNS Lymphoma

Interventions

DRUG: CD19x22 CAR T Cells

Sponsor

University of Colorado, Denver